BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22271891)

  • 21. Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelial‑to-mesenchymal transition pathway.
    Yu C; Chen L; Yie L; Wei L; Wen T; Liu Y; Chen H
    Oncol Rep; 2015 May; 33(5):2402-10. PubMed ID: 25738652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
    Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J
    Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of Forkhead box protein M1 by thiostrepton increases chemosensitivity to doxorubicin in T-cell acute lymphoblastic leukemia.
    Wang JY; Jia XH; Xing HY; Li YJ; Fan WW; Li N; Xie SY
    Mol Med Rep; 2015 Jul; 12(1):1457-64. PubMed ID: 25760224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia.
    Buchner M; Park E; Geng H; Klemm L; Flach J; Passegué E; Schjerven H; Melnick A; Paietta E; Kopanja D; Raychaudhuri P; Müschen M
    Nat Commun; 2015 Mar; 6():6471. PubMed ID: 25753524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteasome inhibitors suppress expression of NPM and ARF proteins.
    Pandit B; Gartel AL
    Cell Cycle; 2011 Nov; 10(22):3827-9. PubMed ID: 22071628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FoxM1 inhibitors as potential anticancer drugs.
    Gartel AL
    Expert Opin Ther Targets; 2008 Jun; 12(6):663-5. PubMed ID: 18479213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deletion of Forkhead Box M1 transcription factor reduces malignancy in laryngeal squamous carcinoma cells.
    Chen W; Yuan K; Tao ZZ; Xiao BK
    Asian Pac J Cancer Prev; 2011; 12(7):1785-8. PubMed ID: 22126565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.
    Uddin S; Ahmed M; Hussain AR; Jehan Z; Al-Dayel F; Munkarah A; Bavi P; Al-Kuraya KS
    Lab Invest; 2009 Oct; 89(10):1115-27. PubMed ID: 19636294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOXM1 is overexpressed in B-acute lymphoblastic leukemia (B-ALL) and its inhibition sensitizes B-ALL cells to chemotherapeutic drugs.
    Consolaro F; Basso G; Ghaem-Magami S; Lam EW; Viola G
    Int J Oncol; 2015 Oct; 47(4):1230-40. PubMed ID: 26316295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Forkhead Box Protein M1 Promotes Nasopharyngeal Carcinoma Cell Tumorigenesis Possibly via the Wnt/β-Catenin Signaling Pathway.
    Yu C; Chen H; Zhao Y; Zhang Y
    Med Sci Monit; 2021 Dec; 27():e931970. PubMed ID: 34911926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S; Sankar R; Varunkumar K; Ravikumar V
    Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors.
    Ahmad A; Wang Z; Kong D; Ali S; Li Y; Banerjee S; Ali R; Sarkar FH
    Breast Cancer Res Treat; 2010 Jul; 122(2):337-46. PubMed ID: 19813088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits xenograft tumor growth.
    Halasi M; Pandit B; Wang M; Nogueira V; Hay N; Gartel AL
    Am J Pathol; 2013 Jul; 183(1):257-65. PubMed ID: 23665201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
    Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
    Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOXM1-induced upregulation of lncRNA OR3A4 promotes the progression of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
    Meng H; Zhao B; Wang Y
    Exp Mol Pathol; 2020 Aug; 115():104451. PubMed ID: 32417392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MED28 and forkhead box M1 (FOXM1) mediate matrix metalloproteinase 2 (MMP2)-dependent cellular migration in human nonsmall cell lung cancer (NSCLC) cells.
    Hsieh NT; Huang CY; Li CC; Wang IC; Lee MF
    J Cell Physiol; 2019 Jul; 234(7):11265-11275. PubMed ID: 30499104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
    Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
    BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.